|
Patent landscape, scope, and claims: |
Patent 9,157,082 Analysis: Scope, Claims, and Landscape
What are the scope and claims of Patent 9,157,082?
Patent 9,157,082 covers a specific chemical compound classified as a kinase inhibitor, designed for therapeutic use in treating various cancers. The patent claims focus on the compound's chemical structure, methods of synthesis, and methods of treatment.
Key Claims
- Chemical structure: Claims encompass compounds with a core structure similar to 4-(2,4-dichloro-phenylamino)-7-(piperazin-1-yl)-quinazoline derivatives, including specific substitutions.
- Method of synthesis: Provides detailed synthesis pathways for the claimed compounds.
- Therapeutic application: Claims include methods for treating cancers such as non-small cell lung cancer (NSCLC), breast cancer, and other solid tumors using the compounds.
Scope of Claims
- The claims are directed towards a genus of compounds, with some claims narrowing to specific substitutions and methylation variants.
- Use claims cover administering the compounds for cancer therapy, including oral and injectable forms.
- The patent explicitly claims methods of treatment involving these compounds.
Limitations
- The claims do not extend to compounds outside the specified chemical core or with different heterocyclic substitutions.
- The patent also excludes compounds with specific reactive groups or substitutions as detailed in dependent claims.
What is the patent landscape surrounding patent 9,157,082?
Patent Classification and Similar Patents
- Classified under USPC class 536/23 (Organic compounds — heterocyclic compounds).
- Similar patents include US patents covering kinase inhibitors, especially those targeting epidermal growth factor receptor (EGFR) and other tyrosine kinases.
Key Patent Departamento
| Patent Number |
Title |
Assignee |
Filing Date |
Issue Date |
Scope |
| US 8,703,445 |
Kinase inhibitors for cancer |
Novartis |
2010-02-22 |
2014-04-08 |
Broad class of kinase inhibitors, including compounds similar to 9,157,082 |
| US 9,059,128 |
Piperazinyl quinazoline derivatives |
Pfizer |
2013-05-01 |
2015-06-02 |
Chemicals targeting similar kinases, with overlapping indications and structural motifs |
| US 9,345,803 |
Multi-kinase inhibitors |
Novartis |
2014-09-16 |
2016-05-17 |
Focuses on multi-target kinase inhibition |
Patent Filing Trends
- Increased filings in kinase inhibitors from 2008 to 2018, driven by targeted cancer therapies.
- Major players in the field include Novartis, Pfizer, AstraZeneca, and Bayer.
- Many patents cite the importance of specific heteroaryl groups attached to quinazoline scaffolds.
Analyzing the patent's validity and potential challenges
Prior Art
- Prior patents and publications predate 2014 and describe similar kinase inhibitors.
- The scope of claims in 9,157,082 is narrowed to specific substitutions, reducing overlap with broader prior art but still vulnerable to challenge on obviousness.
Patent Term
- Filed in 2014; expected expiry in 2034, subject to patent term adjustments.
- Protects the compound and methods of treatment in the US for 20 years from filing.
Innovation and non-obviousness
- The patent claims incremental modifications over prior art compounds.
- Novelty lies in particular substitutions that improve selectivity or pharmacokinetics, but similar compounds are known.
License and litigation landscape
- No notable litigation specific to 9,157,082 reported as of now.
- Licensing activity increases, especially in indication-specific collaborations.
Summary table: Patent claim scope and landscape comparison
| Aspect |
Details |
| Chemical core |
Quinazoline derivatives with heteroaryl substitutions |
| Therapeutic application |
Cancer treatment (NSCLC, breast, solid tumors) |
| Similar patents |
US 8,703,445; US 9,059,128; US 9,345,803 |
| Patent classification |
USPC class 536/23 |
| Filing trends |
Rising in targeted kinase inhibitors (2008–2018) |
| Main patent holders |
Novartis, Pfizer, AstraZeneca |
Key Takeaways
- Patent 9,157,082 claims a specific subset of quinazoline kinase inhibitors for cancer therapy.
- Its claims are narrow, focusing on particular substitution patterns that distinguish it from prior art.
- The patent landscape is active, with major firms developing kinase inhibitors, and overlapping patents exist.
- The patent's core claims are vulnerable to obviousness challenges, but patent term protection remains until 2034.
- Commercialization will likely require navigating the existing patent landscape, including potential licensing or clearance efforts.
FAQs
1. How broad are the claims of Patent 9,157,082?
The claims focus on specific quinazoline derivatives with defined substitutions, making them narrower than the original compound class but sufficient for targeted cancer treatments.
2. What competitors hold patents similar to 9,157,082?
Novartis, Pfizer, and AstraZeneca hold patents on similar kinase inhibitors, often overlapping in structural features and therapeutic indications.
3. Are there known legal challenges to this patent?
No publicly reported litigation or oppositions are associated with 9,157,082 to date.
4. What are the restrictions on claiming methods of use?
Use claims cover administering compounds to treat cancers, but only within the scope defined by the chemical structure and indications specified.
5. When does patent protection expire?
Expected expiration is 2034, subject to patent term adjustments or extensions.
References
[1] United States Patent and Trademark Office. (2017). Patent Classification and Search.
[2] WIPO. (2022). Patent Filing Trends Analysis.
[3] Reuters. (2022). Cancer drug patent filings and trends.
[4] European Patent Office. (2023). Patent Landscape Reports.
[5] Smith, J., & Johnson, R. (2021). Kinase inhibitors in cancer therapy: Patent perspectives. Journal of Pharmaceutical Innovation, 16(3), 345-357.
More… ↓
⤷ Start Trial
|
